Massive potential in these two drugs
#PXS5505 is the first drug to irreversibly inhibit all #LOX and collagen crosslinking
https://pubmed.ncbi.nlm.nih.gov/33513979/
target for fibrotic cancers. ’Up to 20% of ALL cancers are linked to chronic inflammation related fibrosis’. This market is HUGE for Pharmaxis
#PXS6302 ‘miracle’ drug for burn victim
https://www.linkedin.com/posts/pharmaxis_professor-fiona-wood-am-leading-pxs-6302-activity-6950674560866250752-x7xk?utm_source=share&utm_medium=member_ios
Keloid scarring a massive issue in nations which a large percentage of their population has darker skin pigmentation
